IPO bound? CRISPR Therapeutics ups B round to a cool $140M
Gene editing player CRISPR Therapeutics just added a largely unneeded $38 million to its B round with a group of crossover investors in tow …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
